Logo Lanfrica
  • Accueil
  • Atlas
  • Analyses
  • Documentation
  • Sign in

© 2026 Lanfrica. Tous droits réservés. Tous les droits d'auteur des ressources affichées sur le site Web Lanfrica appartiennent aux détenteurs de droits d'auteur d'origine, sauf indication contraire explicite.

Phenotypic Drug Discovery for Human African Trypanosomiasis: A Powerful Approach

Domaine:

healthcare

Type de record:

paper
Créateur:
FreAndPenDon
Éditeur:
MDP
Hôte:
The work began with the screening of a library of 700,000 small molecules for inhibitors of Trypanosoma brucei growth (a phenotypic screen). The resulting set of 1035 hit compounds was reviewed by a team of medicinal chemists, leading to the nomination of 17 chemically distinct scaffolds for further investigation. The first triage step was the assessment for brain permeability (looking for brain levels at least 20% of plasma levels) in order to optimize the chances of developing candidates for treating late-stage human African trypanosomiasis. Eleven scaffolds subsequently underwent hit-to-lead optimization using standard medicinal chemistry approaches. Over a period of six years in an academic setting, 1539 analogs to the 11 scaffolds were synthesized. Eight scaffolds were discontinued either due to insufficient improvement in antiparasitic activity (5), poor pharmacokinetic properties (2), or a slow (static) antiparasitic activity (1). Three scaffolds were optimized to the point of curing the acute and/or chronic T. brucei infection model in mice. The progress was accomplished without knowledge of the mechanism of action (MOA) for the compounds, although the MOA has been discovered in the interim for one compound series. Studies on the safety and toxicity of the compounds are planned to help select candidates for potential clinical development. This research demonstrates the power of the phenotypic drug discovery approach for neglected tropical diseases.

Visit

doi.org

Licenses

https://creativecommons.org/licenses/by/4.0/

Similaires

Discovery of a Carbazole-Derived Lead Drug for Human African TrypanosomiasisTarget-based drug discovery for human African trypanosomiasis: selection of molecular target and chemical matterMatrix metalloproteinase‐9 and intercellular adhesion molecule 1 are powerful staging markers for human African trypanosomiasisDrug development for human African trypanosomiasis targeting its cyanide-insensitive respirationVivli Data Challenge: Genomic-Phenotypic Association for AMR Drug Target DiscoveryKinase Scaffold Repurposing for Neglected Disease Drug Discovery: Discovery of an Efficacious, Lapatanib-Derived Lead Compound for Trypanosomiasis

Discovery of a Carbazole-Derived Lead Drug for Human African Trypanosomiasis

Abstract The protozoan parasite Trypanosoma brucei causes the fatal illness human African trypano

Target-based drug discovery for human African trypanosomiasis: selection of molecular target and chemical matter

SUMMARY Target-based approaches for human African trypanosomiasis (HAT) and related parasites can b

Matrix metalloproteinase‐9 and intercellular adhesion molecule 1 are powerful staging markers for human African trypanosomiasis

Summary Objectives  A critical step before treatment of human African trypanosomiasis (HAT) is th

Drug development for human African trypanosomiasis targeting its cyanide-insensitive respiration

Vivli Data Challenge: Genomic-Phenotypic Association for AMR Drug Target Discovery

GEPHARD: Genomic-Phenotypic Association for AMR Drug Target Discovery Antimicrobial resistance (AMR

Kinase Scaffold Repurposing for Neglected Disease Drug Discovery: Discovery of an Efficacious, Lapatanib-Derived Lead Compound for Trypanosomiasis

Human African trypanosomiasis (HAT) is a neglected tropical disease caused by the protozoan parasite